fam-trastuzumab deruxtecan
E902880
Fam-trastuzumab deruxtecan is an antibody–drug conjugate used primarily to treat HER2-positive cancers by delivering a cytotoxic payload directly to HER2-expressing tumor cells.
Statements (49)
| Predicate | Object |
|---|---|
| instanceOf |
HER2-targeted therapy
ⓘ
antibody–drug conjugate ⓘ anticancer drug ⓘ |
| bindsTo | human epidermal growth factor receptor 2 ⓘ |
| hasAdverseEffect |
alopecia
ⓘ
decreased appetite ⓘ fatigue ⓘ interstitial lung disease ⓘ myelosuppression ⓘ nausea ⓘ neutropenia ⓘ pneumonitis ⓘ vomiting ⓘ |
| hasBoxedWarning |
embryo-fetal toxicity
ⓘ
interstitial lung disease and pneumonitis ⓘ |
| hasBrandName | Enhertu NERFINISHED ⓘ |
| hasComponent |
cleavable tetrapeptide-based linker
ⓘ
topoisomerase I inhibitor payload ⓘ trastuzumab-based monoclonal antibody ⓘ |
| hasDosingInterval | every 3 weeks in many regimens ⓘ |
| hasDrugClass |
HER2-directed antibody–drug conjugate
ⓘ
topoisomerase I inhibitor conjugate ⓘ |
| hasGenericName | trastuzumab deruxtecan NERFINISHED ⓘ |
| hasIndication |
HER2-low unresectable or metastatic breast cancer
ⓘ
HER2-mutant unresectable or metastatic non-small cell lung cancer ⓘ HER2-positive gastroesophageal junction adenocarcinoma ⓘ HER2-positive solid tumors in certain settings ⓘ HER2-positive unresectable or metastatic breast cancer ⓘ HER2-positive unresectable or metastatic gastric cancer ⓘ |
| hasInternationalNonproprietaryName | trastuzumab deruxtecan NERFINISHED ⓘ |
| hasMolecularTarget | ERBB2 NERFINISHED ⓘ |
| hasPayload | deruxtecan ⓘ |
| hasRegulatoryApproval |
European Medicines Agency
NERFINISHED
ⓘ
U.S. Food and Drug Administration NERFINISHED ⓘ |
| hasTargetPopulation |
adults with HER2-low breast cancer
ⓘ
adults with HER2-positive cancer ⓘ |
| hasTherapeuticArea | oncology ⓘ |
| isAdministeredBy | intravenous route ⓘ |
| isCoDevelopedBy | AstraZeneca NERFINISHED ⓘ |
| isContraindicatedIn | patients with known serious hypersensitivity to trastuzumab deruxtecan components ⓘ |
| isDevelopedBy | Daiichi Sankyo NERFINISHED ⓘ |
| isGivenInCombinationWith | premedication for infusion-related reactions in some protocols ⓘ |
| isMetabolizedTo | DXd (deruxtecan) payload ⓘ |
| isUsedFor |
treatment of HER2-expressing cancers
ⓘ
treatment of metastatic cancer ⓘ |
| mechanismOfAction |
binds HER2 on tumor cells and delivers a cytotoxic topoisomerase I inhibitor
ⓘ
induces DNA damage and apoptosis in HER2-expressing tumor cells ⓘ |
| routeOfAdministration | intravenous infusion ⓘ |
| targets | HER2 NERFINISHED ⓘ |
Referenced by (2)
Full triples — surface form annotated when it differs from this entity's canonical label.